Excel with Evidera

Why Evidera?

Testimonials

  • “We have worked successfully with Evidera’s health economics group for several years now across a range of projects. Their research work has been well executed and received and, with the results, they have brought valuable insight to the table to help position the product better.”

    Associate Director, Health Economics and Outcomes Research, Top 20 Pharmaceutical Manufacturer

  • “Your insight and understanding helped to save a product that was in danger of being dropped by corporate marketing/development despite significant sales potential.”

    Head of Corporate Pricing and Economics, Top 10 Pharmaceutical Company

  • “Evidera’s teams have provided evidence generation and value development support, bolstered by ongoing strategy work on our full portfolio of key products, both in early- and late-phase development. This has not only allowed us to build a solid foundation between R&D and our global medical teams, but has also helped us refine our value propositions and plan for further evidence generation activities at critical time points.”

    Vice President of Medical Affairs and R&D, Top 5 Pharmaceutical Manufacturer

  • “[Evidera’s] team was professional and pleasant to deal with and your presentation was informative, well researched and a good value for the money. I think you are the best in the world at what you do.”

    Director of Global Pricing, Top 10 Biopharmaceutical Manufacturer

Our Experts – One of the largest and most well respected teams in the industry

  • 20% of our scientists and consultants have 15+ years of experience, 80% have an advanced degree (MD, PhD, master’s, etc.)
  • Faculty appointments include: McGill University, Johns Hopkins University, University of North Carolina and others
  • 1,100+ active research studies in progress; have conducted tens of thousands in all
  • Authored 2,000+ peer-reviewed publications dating back to 1974, with more than 130 in 2014 alone
  • Experience across all major therapeutic areas, including many rare and orphan diseases
  • Frequently participate on society boards and committees, e.g., International Society for Pharmacoeconomics and Outcomes Research (ISPOR), International Society for Quality of Life Research (ISOQOL), Academy of Managed Care Pharmacy (AMCP), Drug Information Association (DIA), International Society for Pharmacoepidemiology (ISPE), Health Technology Assessment international (HTAi) and Medical Decision Making (MDM)
  • In a recent survey of nine biopharma companies conducted by a leading global management consulting firm, Evidera ranked higher than our top competitors in: quality, ability to execute, analytical/technical capabilities, relationship, content/therapeutic area expertise and breadth of services

Our Ingenuity – Industry pioneers developing new methods, solutions and technologies

  • Developed new methods in modeling and simulation (e.g., STC)
  • Designed novel technology-enabled solutions and platforms (e.g., interactive dossiers, model interfaces)
  • Created the first multi-sponsor consortia for developing a standardized patient-reported outcomes (PRO) instrument and led the development of the first FDA-qualified PRO instrument in the area of chronic obstructive pulmonary disease (COPD)
  • Ongoing thought leadership in Bayesian statistics and comparative effectiveness
  • New statistical methods for targeted comparisons of treatments when network meta analysis is not appropriate
  • Evalytica™: The next-generation healthcare data analytics platform for rapid, efficient analysis across heterogeneous real-world data sources

Our Reach – Global presence and multi-national expertise that enables research in all major markets

  • 300+ researchers and consultants
  • Network of 2,000+ payer experts and advisors worldwide
  • Pricing, reimbursement and market access expertise in 45+ countries
  • Developed economic models for use in HTA submissions in 20+ countries

Cross-disciplinary expertise applied with a client-centric focus

  • Developed economic models that helped to reverse and inform the fast-tracking of a National Institute for Health and Care Excellence (NICE) decision
  • Our Centers of Excellence ensure we remain on the scientific forefront
  • Collaborating with the National Organization for Rare Disorders (NORD) to bring Evidera’s world-class scientific research expertise to NORD and its patient groups
Back to Top